USANew treatments and approvals
Crinecerfont, used together with steroids, approved in the USA for classic CAH
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
On December 13, 2024, the US Food and Drug Administration (FDA) approved a drug called crinecerfont for classic CAH (congenital adrenal hyperplasia). The drug is used together with steroids in children aged 4 years and older and in adults. It reduces the excess male hormone made by the adrenal glands. This allows the disease to be controlled with a lower steroid dose. In the adult study, the daily steroid dose fell by 27% with the drug and by 10% with placebo.
What does it mean for patients and families?
A new way has opened up to reduce the burden of high-dose steroids. Steroid treatment is not stopped; the dose is adjusted with your doctor. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
ABD Gıda ve İlaç Dairesi (FDA): FDA Approves New Treatment for Congenital Adrenal Hyperplasia
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Congenital adrenal hyperplasia (21-hydroxylase deficiency, CAH)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.